You are here: Industry Insights > Bharat Biotech

News List

Bharat Biotech commences Phase III trials for COVAXIN expresspharma
November 17, 2020
Phase III trials will involve 26,000 volunteers across India who will receive two intramuscular injections, approximately 28 days apart.
Bharat Biotech to manufacture Covaxin from Odisha expresspharma
November 09, 2020
Dr Ella informs that the best of the technology will be put in the Odisha unit at a total investment of around Rs 300 crores.
Covaxin may get launched in February 2021: ICMR scientist expresspharma
November 06, 2020
The company had earlier hoped to launch it only in the second quarter of next year.
Bharat Biotech plans Covaxin launch in second quarter of 2021, post requisite approvals expresspharma
November 02, 2020
Bharat Biotech is planning to launch its COVID-19 vaccine in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities, a top company official said.
COVAXIN from Bharat Biotech gets DCGI nod for Phase III clinical trials expresspharma
October 26, 2020
Covaxin, the COVID-19 vaccine candidate from Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR), has received approval from DCGI for phase III clinical trials.
Bharat Biotech in talks with many countries for clinical trials, manufacture of COVAXIN expresspharma
October 26, 2020
Bharat Biotech is in discussions with more than 10 countries that have shown an interest in its potential COVID-19 vaccine, a company executive told Reuters.
Serum India, Bharat Biotech to test intranasal COVID-19 vaccines post regulatory nod: Dr Harsh Vardhan expresspharma
October 19, 2020
He clarified that Phase III clinical trial is generally with thousands of participants, sometimes even close to 30,000 to 40,000 participants.
Bharat Biotech told to provide phase II data of Covaxin before phase III trial expresspharma
October 12, 2020
The SEC also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so far.
Bharat Biotech signs deal with Washington University School of Medicine in St Louis for COVID-19 vaccine expresspharma
September 24, 2020
Bharat Biotech owns the rights to distribute the chimp-adenovirus, single-dose intranasal vaccine candidate in all markets except the US, Japan and Europe.
COVAXIN demonstrates protective efficacy in animal studies: Bharat Biotech expresspharma
September 14, 2020
A two-dose vaccination regimen, administered in 20 rhesus macques, showed increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page